# Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)

> **NCT00729222** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 60 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Comparator: Placebo
- **DRUG:** rolofylline

## Key facts

- **NCT ID:** NCT00729222
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2015-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00729222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00729222, "Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00729222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*